Seres Therapeutics, Inc. (MCRB)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Seres Therapeutics, Inc. reported revenue of $789.0K. The company was profitable, with a net margin of 721.9%. It held $138.19M in total assets against $93.97M in total liabilities.
Key ratios (FY2025)
-11910.1%
Operating margin
721.9%
Net margin
12.9%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $789.0K | $0 | $0 | $7.13M | $144.93M | $33.22M | $34.51M | $28.27M | $32.10M | $21.77M |
| Operating Income | -$93.97M | -$121.31M | -$195.10M | -$179.91M | -$64.49M | -$88.13M | -$71.88M | -$100.28M | -$91.39M | -$92.84M |
| Net Income | $5.70M | $136.0K | -$113.72M | -$250.16M | -$65.58M | -$89.13M | -$70.28M | -$98.94M | -$89.38M | -$91.58M |
| EPS (Diluted) | $0.64 | $0.00 | $-17.77 | $-2.31 | $-0.72 | $-1.12 | — | — | — | — |
| Total Assets | $138.19M | $139.81M | $358.60M | $348.78M | $354.86M | $342.94M | $132.44M | $120.47M | $189.52M | $272.65M |
| Total Liabilities | $93.97M | $126.03M | $403.46M | $338.00M | $223.35M | $168.19M | $180.76M | $168.52M | $128.82M | $140.01M |
| Shareholders' Equity | $44.22M | $13.78M | -$44.86M | $10.78M | $131.51M | $174.75M | -$48.32M | -$48.05M | $60.70M | $132.63M |
| Cash & Equivalents | $45.77M | $30.79M | $127.97M | $163.03M | $180.00M | $116.05M | $65.13M | $85.82M | $36.09M | $54.54M |
| Operating Cash Flow | $1.12M | -$148.61M | -$117.35M | -$228.82M | $6.69M | -$93.61M | -$76.52M | -$62.85M | -$75.52M | $43.92M |
| Capital Expenditures | $252.0K | $380.0K | $7.97M | $9.82M | $9.57M | $591.0K | $1.00M | $1.94M | $4.68M | $21.49M |
| Shares Outstanding | 9.56M | 8.65M | 135.04M | 125.22M | 91.89M | 91.46M | 70.14M | 40.94M | 40.57M | 40.36M |